Long-term follow-up of BRL-101 in people with beta-thalassemia
Follows people with transfusion-dependent beta-thalassemia after an infusion of BRL-101 over time.
Plain-language title generated from the registry record
Registry title: Long-term Follow-up Study of BRL-101 for TDT
Key facts
- Where
- Changsha, Guangxi, Guangzhou, Nanning, Shenzhen, and Tianjin, ChinaSee the 7 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 3 and 35 years old?
Source: NCT06298630, who can take part
Where in China
- Xiangya Hospital of Central South UniversityChangsha, ChinaTaking people
- The First Affiliated Hospital of Guangxi Medical UniversityGuangxi, ChinaTaking people
- Sun Yat Sen Memorial Hospital of Sun Yat sen UniversityGuangzhou, ChinaNot yet recruiting
- Nanfang Hospital, Southern Medical UniversityGuangzhou, ChinaNo longer taking part
- No. 923 Hospital of Joint Support Force of Chinese People 's Liberation Army HospitalNanning, ChinaNot yet recruiting
- Shenzhen Children's HospitalShenzhen, ChinaNot yet recruiting
- Tianjin Institute of HematologyTianjin, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bioray Laboratories
- Trial code
- NCT06298630
- Record updated
- 21 July 2026
- Original description
Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.Read full original descriptionShow less
Long-term Follow-up Study of BRL-101 in the Treatment of Transfusion-dependent β-thalassemia
Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.
Inclusion: Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s); Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.
Exclusion: There are no exclusion criteria for this study.